UK Competition Commission retains IMS's undertakings on specialized pharmaceutical data services
MLex Summary: The UK Competition Commission has provisionally decided to retain undertakings that IMS Health Incorporated (IMS) offered to obtain merger approval for its acquisition of Pharmaceutical Marketing Services in 1999....To view the full article, register now.
Already a subscriber? Click here to view full article